When Novo Nordisk’s semaglutide trials for Alzheimer’s disease reported failure in November 2025, the headlines declared a setback for the most celebrated drug class in a generation. The EVOKE and EVOKE+ studies — 3,808 patients, two years of follow-up, the largest GLP-1 trials ever conducted in a neurodegenerative disease — found that oral semaglutide did not significantly slow Alzheimer’s disease progression compared to placebo. Novo Nordisk’s stock fell 8 percent. The story was widely read as a correction to GLP-1 hype.
What the headlines largely missed was what happened six days later.
On December 1, 2025, Imperial College London published results from a trial of liraglutide — a different GLP-1 drug delivered by injection rather than pill — in Alzheimer’s patients. The injectable liraglutide produced nearly 50 percent less brain volume loss and an 18 percent slower decline in cognitive function compared to placebo, results published in Nature. The contrast with the Novo failure was striking and scientifically revealing: semaglutide taken as a pill may not reach the brain in sufficient concentration, while injectable liraglutide, which can cross the blood-brain barrier in small amounts, appears to produce meaningful neuroprotective effects. The delivery route, not the drug class, may be the critical variable for neurological applications.
This is the GLP-1 story of 2025 and 2026: not a simple triumph or a simple failure, but an expanding and increasingly complex picture of a drug class that is rewriting the rules of metabolic medicine while simultaneously revealing the limits of what any single formulation can do.
What GLP-1 Drugs Actually Do
Glucagon-like peptide-1 is a hormone naturally produced in the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. GLP-1 receptor agonist drugs — semaglutide, liraglutide, tirzepatide — mimic this hormone at pharmacological doses, producing powerful effects on blood sugar and appetite that have made them transformative for type 2 diabetes and obesity treatment.
The reason researchers began suspecting these drugs could do far more than manage metabolism is that GLP-1 receptors are distributed throughout the body in ways that no one fully appreciated when the first GLP-1 drug was approved. They are present in the heart, kidneys, liver, pancreas, lungs, and critically — in multiple regions of the brain, including areas involved in inflammation, reward processing, neuroprotection, and neurodegeneration. When a drug designed to mimic a gut hormone turns out to engage receptors across virtually every major organ system, the implications for diseases beyond diabetes become impossible to ignore.
The Cardiovascular Foundation
The clearest demonstration of GLP-1’s systemic reach came from the cardiovascular outcomes trials. The SELECT trial — more than 17,000 adults from 41 countries — demonstrated that semaglutide substantially reduced cardiovascular death, heart attack, and stroke in people with obesity but without diabetes. One of the key findings was that the cardiovascular effects appeared even before noticeable weight loss, suggesting the drug acts directly on the heart and vascular system rather than through metabolic improvement alone.
The magnitude is now well-documented. In the SOUL trial of nearly 10,000 patients, semaglutide led to a 14 percent reduction in cardiovascular death, heart attack, and stroke versus placebo — a finding that drove the EMA to approve semaglutide as the first stroke management therapy in September 2025. A large real-world study called STEER found that semaglutide demonstrated a 57 percent greater reduction in major cardiovascular adverse events compared with tirzepatide in adults with overweight and established cardiovascular disease — suggesting the drugs within the GLP-1 class are not interchangeable for all indications.
Organ by Organ: What the 2025-2026 Evidence Shows
The breadth of GLP-1 effects across organ systems is now documented well enough to assess honestly — identifying where the evidence is strong, where it is preliminary, and where it has failed.
Liver disease produced one of the most striking results of 2025. The ESSENCE trial found that semaglutide 2.4 mg produced resolution of steatohepatitis without worsening fibrosis in 62.9 percent of patients with metabolic dysfunction-associated steatohepatitis, compared to 34.3 percent with placebo. The FDA granted accelerated approval for this indication in August 2025. This is not a metabolic side effect — it is a direct liver-protective action with imaging-confirmed structural improvement, what one physician described as “not just not making it worse; we’re having resolution of some of the cirrhosis and scarring.”
Kidney disease: The FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24 percent in patients with type 2 diabetes and chronic kidney disease, while also slowing annual estimated glomerular filtration rate decline — resulting in a dedicated FDA indication for semaglutide in this population.
Sleep apnea: Tirzepatide’s SURMOUNT-OSA trial demonstrated a reduction of 25 to 29 apnea-hypopnea events per hour versus approximately 5 with placebo, alongside 17 to 20 percent body weight reduction. Tirzepatide received FDA approval for obstructive sleep apnea — the first medication approved specifically for this indication.
Addiction: A target trial emulation study of more than 120 million patients found that tirzepatide was associated with a 40 percent relative reduction in alcohol use disorder incidence, with similar signals for semaglutide and liraglutide. The proposed mechanism involves GLP-1 receptor expression in reward-related brain regions dampening dopaminergic drug-reward signaling. Early data also suggest slowing of motor disability progression in Parkinson’s disease.
Alzheimer’s disease requires the most nuanced treatment of any indication. Oral semaglutide failed in the EVOKE trials. Injectable liraglutide showed meaningful neuroprotective effects in the Imperial trial. The key mechanistic distinction appears to be brain penetration: injectable liraglutide can enter the brain, though only in small amounts, while oral semaglutide — designed to survive the digestive system — may be blocked from certain brain regions including the hippocampus by its fatty-acid structure. Observational data consistently show GLP-1 users have lower dementia risk — but prevention is different from treatment of established disease, and the EVOKE failure confirms this distinction matters clinically.
The Inflammation Hypothesis
What connects these diverse effects across such different organ systems? The leading mechanistic hypothesis is systemic inflammation reduction. GLP-1 receptor activation appears to suppress inflammatory signaling through multiple pathways — reducing levels of C-reactive protein, interleukin-6, and tumor necrosis factor-alpha across different tissues. Inflammation is a common driver of cardiovascular disease, liver disease, kidney disease, neurodegeneration, and metabolic dysfunction. A drug that reduces systemic inflammation through a broadly distributed receptor system is, in a sense, doing the same thing everywhere — reducing the inflammatory burden that underlies multiple chronic diseases simultaneously.
Researchers note that GLP-1 drugs improve brain insulin resistance, improve neuronal survival, reduce plaques in some animal studies, reduce brain inflammation, and communicate to receptors on neurons — a constellation of effects targeting multiple disease mechanisms simultaneously. This multi-pathway activity is what makes the drugs potentially useful for complex diseases like neurodegeneration, and also what makes it difficult to predict which specific manifestations will respond and which will not. The EVOKE failure, set against the liraglutide success, suggests that the inflammation hypothesis is correct but that delivery to the relevant tissue is the critical variable the hypothesis alone does not specify.
The Oral Revolution and Accessibility
A development that received less attention than the clinical trials is the formulation shift underway. Oral semaglutide 25 mg, available since January 2026, marked a significant advance using salcaprozate sodium technology featuring a tablet design that locally raises pH to improve absorption. In the phase 3 OASIS 4 trial, the 25 mg tablet delivered mean weight loss of 13.6 percent in patients with obesity, with 79.2 percent achieving at least 5 percent weight loss versus 31.1 percent with placebo.
Separately, orforglipron — a first-in-class oral, small-molecule, non-peptide GLP-1 receptor agonist from Eli Lilly — is awaiting FDA action. Unlike semaglutide, which is a peptide requiring special formulation to survive digestion, orforglipron is a small molecule that can be absorbed normally as a conventional pill. If approved, it could dramatically expand access to a drug class that currently requires weekly self-injection or specialized oral formulation for most patients — an important consideration for the billions of people globally who might benefit from GLP-1’s systemic anti-inflammatory effects.
What Remains Genuinely Uncertain
The failure of semaglutide in Alzheimer’s treatment illustrates that GLP-1 effects are not universal across all inflammatory conditions or all formulations. The brain is different — its protective barriers, specialized inflammatory biology, and the irreversible nature of neuronal loss create a different therapeutic context than peripheral organ disease.
Long-term effects of GLP-1 drugs in healthy individuals — for longevity or prevention rather than disease treatment — have not been systematically studied in randomized trials. Muscle loss alongside fat loss during GLP-1 treatment is a genuine concern for older patients and those with sarcopenia, where preserving lean mass is as important as reducing fat. The economics of GLP-1 access remain unresolved — these are expensive drugs at list prices that many patients and health systems cannot sustain, and the populations that might benefit most from systemic anti-inflammatory effects often have the least ability to pay.
Whether the observational signal showing reduced dementia risk in GLP-1 users reflects a true preventive effect — or confounding by the healthier metabolic profile of GLP-1 users — requires prospective randomized trials that are only beginning to be designed.
Why It Matters
The recognition that a drug class developed for blood sugar control has direct protective effects on the heart, liver, kidneys, brain, and reward systems — through mechanisms partially independent of weight loss — represents a fundamental reframing of what these drugs are. They are not primarily weight loss drugs that happen to reduce cardiovascular risk. They are systemic anti-inflammatory agents that happen to produce weight loss as one of their prominent effects. That reframing has profound implications for which patients should receive them, for how long, at what dose, and for what primary indication. Medicine is only beginning to work through those implications — and the pace of new indications, new formulations, and new clinical evidence in 2025 and 2026 suggests the working-through will continue for years.
Closing Human Dimension
The patient who started taking semaglutide to lose weight and discovered that their joints hurt less, their sleep apnea improved, and their doctor was pleased by their liver enzymes is not an anecdote. They are a biological signal about what these drugs are actually doing — reducing the inflammatory burden that was quietly driving multiple simultaneous health problems. The scientific challenge now is to understand that signal well enough to use it deliberately, in the right patients, for the right indications, before the diseases it could prevent have already arrived.
Sources
1. Pharmacy Times / APhA 2026. “GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease.” June 2026. https://www.pharmacytimes.com/view/apha2026-glp-1-therapies-are-rewriting-the-rules-of-metabolic-disease
2. NeurologyLive. “Repositioning GLP-1 Drugs for Neurologic Disease.” June 2026. https://www.neurologylive.com/view/repositioning-glp-1-drugs-neurologic-disease-evidence-advances-outlook
3. Imperial College London. “Weight-loss drugs and Alzheimer’s disease: is there hope for the future?” February 2026. https://www.imperial.ac.uk/news/articles/medicine/brain-sciences/2026/weight-loss-drugs-and-alzheimers-disease–is-there-hope-for-future-/
4. Nature Medicine. “Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial.” December 2025. https://www.nature.com/articles/s41591-025-04106-7
5. BioPharma Dive. “Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies.” November 2025. https://www.biopharmadive.com/news/novo-glp1-alzheimers-trials-evoke/806256/
6. Science / AAAS. “Popular obesity drug fails in hotly anticipated Alzheimer’s trials.” https://www.science.org/content/article/popular-obesity-drug-fails-hotly-anticipated-alzheimer-s-trials
7. ALZFORUM. “Semaglutide.” Therapeutics database, updated April 2026. https://www.alzforum.org/therapeutics/semaglutide
8. U.S. News Health. “The GLP-1 Effect: Beyond Weight Loss and into Longevity.” January 2026. https://health.usnews.com/wellness/articles/the-glp-1-effect
9. Alzheimer’s Association. “GLP-1s and Alzheimer’s: What You Need to Know.” October 2025. https://www.alz.org/blog/2025/glp-1s-and-alzheimer-s-what-you-need-to-know
Idea originated at artificialideas.org. Article researched and written by Claude Sonnet 4.6. Published at artificialideas.org.
Artificial Ideas 